ATE401890T1 - CONTROLLED RELEASE FORMULATION CONTAINING LAMOTRIGINE - Google Patents

CONTROLLED RELEASE FORMULATION CONTAINING LAMOTRIGINE

Info

Publication number
ATE401890T1
ATE401890T1 AT03748504T AT03748504T ATE401890T1 AT E401890 T1 ATE401890 T1 AT E401890T1 AT 03748504 T AT03748504 T AT 03748504T AT 03748504 T AT03748504 T AT 03748504T AT E401890 T1 ATE401890 T1 AT E401890T1
Authority
AT
Austria
Prior art keywords
controlled release
release formulation
formulation containing
formulations
lamotrigine
Prior art date
Application number
AT03748504T
Other languages
German (de)
Inventor
Sunil Sadanand Nadkarni
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE401890T1 publication Critical patent/ATE401890T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

Rapidly disintegrating multiparticulate controlled release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the formulations. It provides better control of blood plasma levels than conventional tablet formulations that is administered once or more times a day.
AT03748504T 2002-06-07 2003-06-06 CONTROLLED RELEASE FORMULATION CONTAINING LAMOTRIGINE ATE401890T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38679502P 2002-06-07 2002-06-07

Publications (1)

Publication Number Publication Date
ATE401890T1 true ATE401890T1 (en) 2008-08-15

Family

ID=29736213

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03748504T ATE401890T1 (en) 2002-06-07 2003-06-06 CONTROLLED RELEASE FORMULATION CONTAINING LAMOTRIGINE

Country Status (12)

Country Link
US (2) US7939102B2 (en)
EP (1) EP1513535B1 (en)
AT (1) ATE401890T1 (en)
AU (1) AU2003267808A1 (en)
BR (1) BRPI0311701B8 (en)
CA (1) CA2488868C (en)
DE (1) DE60322389D1 (en)
DK (1) DK1513535T3 (en)
ES (1) ES2311108T3 (en)
PT (1) PT1513535E (en)
RU (1) RU2328274C2 (en)
WO (1) WO2003104192A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089808A1 (en) * 2001-05-09 2002-11-14 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (en) 2002-07-16 2004-01-29 Bayer Ag Medicinal products containing vardenafil hydrochloride trihydrate
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
WO2005051350A2 (en) * 2003-10-28 2005-06-09 Torrent Pharmaceuticals Limited Water dispersible tablet
EP1737405A2 (en) * 2004-04-06 2007-01-03 RPG Life Sciences Limited Mouth dissolvable and meltable, and water dispersable delivery formulation
DE102004023069A1 (en) * 2004-05-11 2005-12-08 Bayer Healthcare Ag New dosage forms of the PDE 5 inhibitor vardenafil
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
DE102005001989A1 (en) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenous formulations of PDE inhibitors
WO2006088814A2 (en) * 2005-02-15 2006-08-24 Jazz Pharmaceuticals Dosage form and method for sustained release of a substituted pyrazine compound
DE102005009241A1 (en) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Dosage forms with controlled bioavailability
DE102005009240A1 (en) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Dosage forms with improved pharmacokinetic properties
JP2008531605A (en) * 2005-03-04 2008-08-14 インテルジェネクス コーポレイション Delayed release oral drug product and method for producing the same
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
BRPI0616633A2 (en) * 2005-09-29 2011-06-28 Bayer Healthcare Ag pde inhibitors and combinations thereof for the treatment of urological disorders
US20100184769A1 (en) * 2007-06-13 2010-07-22 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
TWI547282B (en) 2007-07-02 2016-09-01 愛戴爾製藥股份有限公司 Orally disintegrating tablet compositions of lamotrigine
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
US20090181084A1 (en) * 2008-01-15 2009-07-16 Ta-Ping Liao Oral fast-disintegrating tablet including particles of slowly-releaseable ascorbic acid
US20090196924A1 (en) * 2008-02-04 2009-08-06 Pramod Kharwade Controlled-release lamotrigine formulations
US8133506B2 (en) 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
FR2930147B1 (en) * 2008-04-18 2013-02-08 Flamel Tech Sa SOLID ORAL FORM WITH A DOUBLE RELEASE PROFILE
CN102316864B (en) * 2009-01-22 2015-04-01 雅培医疗保健私人有限公司 Chronotherapeutic pharmaceutical composition
EP2564836A1 (en) 2009-05-20 2013-03-06 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
US20110052686A1 (en) * 2009-09-03 2011-03-03 Ranbaxy Laboratories Limited Modified release lamotrigine tablets
MX2012010229A (en) 2010-03-04 2012-12-05 Wockhardt Ltd Modified release dosage form.
RU2633655C1 (en) * 2016-05-17 2017-10-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Device for dosed opening of microcapsules
WO2018142336A1 (en) * 2017-02-03 2018-08-09 Jubilant Generics Limited Lamotrigine suspension dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
IL100796A (en) 1991-01-30 1998-09-24 Wellcome Found Water-dispersible tablets containing aciclovir or lamotrigine
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
CA2483103A1 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AU2003260336C1 (en) * 2002-07-29 2008-05-29 Glaxo Group Limited Sustained release formulations comprising lamotrigine

Also Published As

Publication number Publication date
DK1513535T3 (en) 2008-11-17
EP1513535A2 (en) 2005-03-16
AU2003267808A1 (en) 2003-12-22
RU2004139088A (en) 2005-11-20
PT1513535E (en) 2008-10-31
US20110123618A1 (en) 2011-05-26
DE60322389D1 (en) 2008-09-04
ES2311108T3 (en) 2009-02-01
CA2488868C (en) 2010-05-11
BR0311701A (en) 2005-03-08
RU2328274C2 (en) 2008-07-10
EP1513535B1 (en) 2008-07-23
BRPI0311701B1 (en) 2018-05-29
US20040043996A1 (en) 2004-03-04
CA2488868A1 (en) 2003-12-18
BRPI0311701B8 (en) 2021-05-25
WO2003104192A2 (en) 2003-12-18
AU2003267808A8 (en) 2003-12-22
US7939102B2 (en) 2011-05-10
WO2003104192A3 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
ATE401890T1 (en) CONTROLLED RELEASE FORMULATION CONTAINING LAMOTRIGINE
IL280818A (en) Methods for producing alpha-galactosidase a compositions
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
DK0703786T3 (en) Use of nona- and decapeptides for the manufacture of a medicament for the treatment of AIDS
MXPA05008406A (en) Phenylacetamides and their use as glucokinase modulators.
NO20053077D0 (en) Therapeutic formulations for the treatment of beta-amyloid-related diseases.
MXPA04011612A (en) Ophthalmological use of roflumilast for the treatment of diseases of the eye.
EP1374935A4 (en) Medical syringe, and method of producing the same
HUP0401978A2 (en) Tamsulosin tablets
DE50008336D1 (en) MULTILAYER TABLET FOR THE ADMINISTRATION OF A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
AU7031500A (en) Therapeutic quinazoline compounds
PT998287E (en) USES OF LEVOBUPIVACAINE
WO2005055955A3 (en) DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
NO331082B1 (en) Formulation of kahalalide F, comprising such a formulation, as well as reconstituted solution thereof and use of a diluted reconstituted solution for the manufacture of a medicament for the treatment of cancer
AU2003271021A1 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
WO2003039539A3 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
MY136059A (en) Swallow tablet comprising paracetamol
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
HUP0401782A2 (en) New anhydrous crystalline forms of gabapentin
SE0102887D0 (en) New formulation
MXPA01007952A (en) L-arginine based formulations for treating diseases and methods of using same.
ATE293445T1 (en) PRODUCTION OF PURE STEREOISOMERS OF TRICYCLO-(5.2.1.0(2.6))-DEC-9-YL-XANTHOGENATE AND THEIR USE AS MEDICINAL PRODUCTS
NZ515173A (en) Treatment of hypersensitivity reaction disorders
GB0216027D0 (en) New therapeutic use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties